XML 63 R44.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Nov. 28, 2018
Aug. 30, 2018
Jan. 02, 2018
Dec. 31, 2018
Nov. 28, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Jul. 10, 2017
Feb. 17, 2017
Money market funds, cash equivalent       $ 20,400         $ 32,100       $ 20,400 $ 32,100    
Working capital       29,500                 29,500      
Net trade receivable       51         139       51 139    
Grants receivable       716         641       716 641    
Allowance for doubtful accounts       $ 100         422       $ 100 422    
Ownership interest       20.00%                 20.00%   99.80%  
Unrealized gain on available-for-sale securities, net of taxes                         521    
Intangible asset, useful life                         10 years      
Foreign currency translation adjustment, net of tax                         $ 1,303 668    
Accrued payment for interest and penalities                        
Federal tax rates                         21.00% 34.00%    
Repatriation of foreign earnings                           $ 227    
Revenues, net       758   $ 982 $ 2,547 $ 701 $ 945 $ 1,636 $ 376 $ 333 $ 4,988 3,458 [1]    
Minimum [Member]                                
Estimated useful life                         3 years      
Maximum [Member]                                
Ownership interest                               50.00%
Estimated useful life                         10 years      
Common Stock [Member]                                
Foreign currency translation adjustment, net of tax                            
Parent Company [Member]                                
Percentage of ownership before transaction   80.40%                            
Percentage of ownership after transaction   40.20%                            
Parent Company [Member] | Common Stock [Member]                                
Number of shares owned 1,700,000       1,700,000                      
Percentage of outstanding common stock 4.80%                       4.80%      
Juvenescence Limited [Member]                                
Ownership interest   5.60%                            
Percentage of ownership before transaction   5.60%                            
Percentage of ownership after transaction   45.80%                            
AgeX [Member]                                
Percentage of outstanding common stock         40.20%                      
Unrealized loss on equity securities         $ 4,200                      
AgeX [Member] | Other Income and Expenses, Net [Member]                                
Unrealized gain on available-for-sale securities, net of taxes                         $ 481      
Hadasit Bio-Holdings, Ltd [Member]                                
Reclassification of adjustments on unrealized gain of available-for-sale-securities     $ 328                          
Hadasit Bio-Holdings, Ltd [Member] | Other Income and Expenses, Net [Member]                                
Unrealized gain on available-for-sale securities, net of taxes                         677      
Alameda Lease and Cell Cure Lease [Member]                                
Certificate of deposit       812                 812      
Alameda Lease and Cell Cure Lease [Member] | Prepaids and Other Current Assets [Member]                                
Certificate of deposit       346                 346      
Alameda Lease and Cell Cure Lease [Member] | Deposits and Other Long-term Assets [Member]                                
Certificate of deposit       466                 466      
Alameda Lease [Member] | January 24, 2019 [Member]                                
Decrease in security deposit                         78      
Working capital       $ 346                 346      
Research and Development Arrangement [Member]                                
Revenues, net                         308 308    
Deferred revenues                              
Revenue information related to transaction price                         There were no deferred revenues related to unsatisfied performance obligations in the consolidated balance sheet as of December 31, 2018. As of December 31, 2018, BioTime had not met any milestones that would require adjustment of the transaction price.      
Subscription and Advertisement Revenues [Member] | Life Map Sciences [Member]                                
Revenues, net                         $ 700 $ 1,400    
Deferred revenues                              
[1] Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.